December 18
1:00 pm - 1:30 pm EST

LOCAL TIME

Accelerating kidney disease clinical trials: The power of data driven patient recruitment

Discover how Natera and ENYO Pharma accelerated clinical trial enrollment with a data-informed approach to Alport Syndrome patient recruitment.

This real-world case study will explore the successful utilization of Natera’s proprietary Clinical Trial Support service, including:

  • Clinical trial site selection tool
  • Cohorting and clinical review
  • Patient and physician outreach services

ENYO Pharma will provide their perspective on:

  • Working with Alport clinicians and the Alport Syndrome Foundation to design a science-rich and patient friendly study
  • Partnering with Natera on data needs and patient identification
  • Managing stakeholders to rapidly accrue study participants in the US

register now
register for the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from Endpoints News and/or the sponsor(s). View how we use your data here.

If you are experiencing problems with your registration, please try the Zoom registration page.

Bryce Powerman

Bryce Powerman

Director of Business Development, Natera

Bryce Powerman is a healthcare professional, patient advocate, and survivor of DOCK8 deficiency, an ultra-rare primary immunodeficiency. Diagnosed at the National Institutes of Health (NIH) after a lengthy diagnostic odyssey, he eventually underwent a life-saving pediatric bone marrow transplant in a first-in-human trial. Bryce serves as the Director of Business Development at Natera, a leading genetic testing company in the renal space, where he champions early genetic testing and proactive education as critical tools for improving patient outcomes.

Pete Leone

Pete Leone

Head of Business Development & Licensing, ENYO Pharma

Pete Leone is a seasoned life sciences entrepreneur with over 30 years of success in biopharmaceuticals and medical devices, spanning public and private sectors. He has played a key role in high-value deals, such as a $1.7 billion potential agreement between Bicycle Therapeutics and Genentech and a $3.7 billion partnership for hepatitis B therapies at Arrowhead Pharmaceuticals. Pete has founded three venture backed companies, including Mersana Therapeutics, and has extensive experience in orphan diseases, oncology and other therapeutic areas. A Dartmouth College and Stanford MBA graduate, he has also contributed as a board member for corporate and nonprofit organizations like SeromYx and NPH USA.

Libby Valenti
moderator

Libby Valenti

Director of Clinical Strategy and Development, Natera

Libby Valenti is a board-certified genetic counselor with over two decades of clinical experience in genetic counseling. Currently, she serves as the Director of Clinical Strategy and Development at Natera, where she leads Clinical Trial Support programs, including patient matching. Her deep understanding of patient needs and clinical nuances has been instrumental in creating a robust framework that aligns patients with the most suitable clinical trials. Her commitment to personalized care is a key driver in successfully connecting patients with new treatment avenues and advancing medical research in the field of genetics.